Retinal drugs market growth driven by aging population, rising AMD prevalence, and advances in ophthalmic drug delivery and retinal disease treatment innovation.

Eylea, developed by Regeneron, is the world’s leading treatment for age-related macular degeneration, a common cause of blindness in older adults. Since its launch in 2013, Eylea has become a major ...

Given that DED reduces the quality of life and health of patients, numerous basic and clinical studies in the field of ophthalmology have been performed to elucidate its pathophysiology, new ...

(Reuters) -German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals ...

Despite significant advances in understanding the epidemiology ... Verteporfin photodynamic therapy has been an established treatment for subfoveal myopic CNV for many years, but this treatment does ...

For prostate cancer, a shorter, high-dose radiation course could be as effective as standard treatments. Meanwhile, simpler surgeries may suffice for low-risk cervical cancer, potentially easing ...

kDepartment of Gynecology and Obstetrics, Hospital Anregiomed Ansbach, Ansbach, Germany lDepartment of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany mViDia Christliche ...

The launch of Eylea 8 mg, offering longer treatment intervals, provided a boost to sales, especially in Japan and the EU. Please note that Bayer’s HealthCare unit co-develops Eylea with ...

(RTTNews) - Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak ...

Management attributed the quarter’s performance to a combination of market headwinds in ophthalmology and strong advances across the broader portfolio. Notably, the decline in EYLEA sales was ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research across more than 25 types of cancer and multiple treatment settings from the company’s broad ...